Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail aims to outsmart resistant prostate cancer

NCT ID NCT06922318

Recruiting now Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a two-step treatment for men with metastatic prostate cancer that no longer responds to standard hormone therapy. First, patients receive a combination of testosterone and an experimental drug called ZEN-3694, followed by a mix of enzalutamide and ZEN-3694. The goal is to see if this sequence can shrink tumors and delay cancer progression. About 50 participants will be enrolled at Johns Hopkins.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Testosterone cypionate, ZEN-3694, enzalutamide, and LHRH analogues
What this could lead to
If successful, this sequential therapy could improve tumor shrinkage and extend the time before prostate cancer progresses in patients who have stopped responding to standard hormone treatments.
What could go wrong
This is a small early-phase trial (50 participants) with no control group, so results may not apply broadly. The combination of hormones and experimental drugs may cause side effects like fatigue, hot flashes, or liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION RESISTANT PROSTATE CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    RECRUITING

    Baltimore, Maryland, 21205, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.